Literature DB >> 15481148

C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level.

Marion Jurk1, Bettina Schulte, Andrea Kritzler, Bernhard Noll, Eugen Uhlmann, Tanja Wader, Christian Schetter, Arthur M Krieg, Jörg Vollmer.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated deoxycytosine-deoxyguanosine (CpG) motifs are very potent inducers of the innate immune system, mimicking the effects of bacterial DNA. CpG ODN are recognized by Toll-like receptor 9 (TLR9). Three classes of TLR9 agonists have been described: B-Class CpG ODN that induce strong B- and NK-cell activation and A-Class ODN that induce very high levels of IFN-alpha by plasmacytoid dendritic cells. The recently described C-Class ODN combine most efficiently properties of A- and B-Class ODN in that they induce strong B-cell activation comparable to B-Class ODN together with IFN-alpha secretion comparable to A-Class ODN. Here, we investigate sequence requirements of C-Class ODN regarding optimal IFN-alpha secretion. Sequence as well as backbone modifications like 2'-O-methyl modifications especially in the 5' part of the ODN influence IFN-alpha-producing capacity. Kinetic studies on mRNA level for CD69, IFN-gamma, IP-10 and IL-18 by semi-quantitative PCR demonstrated differences in mRNA transcription for some cytokines suggesting different regulatory mechanisms for different ODN classes. High amounts of IP-10 mRNA and protein as well as up-regulation of IL-18 mRNA were observed especially for the A- and C-Classes. According to these data, C-Class ODN can be described as strong Th1 inducers with the stimulation of type I and II interferon as well as IP-10 production and strong NK activation. These characteristics can be availed to induce potent anti-tumor or anti-viral effects. Consequently, C-Class CpG ODN represent ideal drug candidates for anti-viral and/or anti-tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481148     DOI: 10.1016/j.imbio.2004.02.006

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  18 in total

1.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

2.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  CpG-B oligodeoxynucleotides inhibit TLR-dependent and -independent induction of type I IFN in dendritic cells.

Authors:  Yi C Liu; Reginald C Gray; Gareth A D Hardy; John Kuchtey; Derek W Abbott; Steven N Emancipator; Clifford V Harding
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

4.  Activation of Innate Immune Responses by a CpG Oligonucleotide Sequence Composed Entirely of Threose Nucleic Acid.

Authors:  Margaret J Lange; Donald H Burke; John C Chaput
Journal:  Nucleic Acid Ther       Date:  2018-12-11       Impact factor: 5.486

5.  Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  Antiviral Res       Date:  2019-06-25       Impact factor: 5.970

6.  DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo.

Authors:  Christopher R Lucas; Patrick D Halley; Amjad A Chowdury; Bonnie K Harrington; Larry Beaver; Rosa Lapalombella; Amy J Johnson; Erin K Hertlein; Mitch A Phelps; John C Byrd; Carlos E Castro
Journal:  Small       Date:  2022-05-28       Impact factor: 15.153

7.  Integrative analysis suggests cell type-specific decoding of NF-κB dynamics.

Authors:  Erik W Martin; Alicja Pacholewska; Heta Patel; Himanshu Dashora; Myong-Hee Sung
Journal:  Sci Signal       Date:  2020-02-25       Impact factor: 8.192

8.  Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.

Authors:  Amber Troy; Sandra C Esparza-Gonzalez; Alicia Bartek; Elizabeth Creissen; Linda Izzo; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2020-06-06       Impact factor: 3.131

9.  CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production.

Authors:  Matthew P Bernard; Richard P Phipps
Journal:  Clin Immunol       Date:  2007-08-28       Impact factor: 3.969

10.  CpG-Oligodeoxynucleotide Treatment Protects against Ionizing Radiation-Induced Intestine Injury.

Authors:  Chao Zhang; Jin Ni; Bai-Long Li; Fu Gao; Hu Liu; Wen Liu; Yi-Juan Huang; Jian-Ming Cai
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.